Skip to content
2000
Volume 21, Issue 3
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

As the third most prevalent cancer, there is no convincing treatment for colorectal cancer. Growth Hormone-releasing Hormone (GHRH) is an important hormone for the growth and maturity of humans and other animals. Also, recent studies show both GHRH and GHRH receptor to be expressed in many types of cancers, such as lung, breast, colon, ovarian, gastric, and pancreatic cancer. GHRH has been shown to augment the growth and proliferation of cancer cells in and studies, but studies have shown that its antagonist can inhibit the growth or even metastasis of cancer cells. The development of many classes of GHRH-R antagonists over the past three decades has shown strong and growth inhibitory effects on cancer. The present study is an attempt to review the studies on the association between GHRH and colorectal cancer and examine if the hormone can be targeted for therapy or used as a prognostic marker for colorectal cancer or not.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947278625240304050815
2024-03-12
2025-09-05

  • From This Site

    /content/journals/cctr/10.2174/0115733947278625240304050815
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KuipersE.J. GradyW.M. LiebermanD. Colorectal cancer.Nat. Rev. Dis. Primers2015111506510.1038/nrdp.2015.65 27189416
     [Google Scholar]
  2. LiY. LiY. XiaZ. Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.Aging (Albany NY)20211323255182554910.18632/aging.203771 34898475
     [Google Scholar]
  3. GuilleminR. BrazeauP. BöhlenP. EschF. LingN. WehrenbergW.B. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.Science1982218457258558710.1126/science.6812220 6812220
     [Google Scholar]
  4. KahánZ. ArencibiaJ.M. CsernusV.J. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.J. Clin. Endocrinol. Metab.199984258258910.1210/jc.84.2.582 10022420
     [Google Scholar]
  5. SchallyA.V. Comaru-SchallyA.M. PlonowskiA. NagyA. HalmosG. RekasiZ. Peptide analogs in the therapy of prostate cancer.Prostate200045215816610.1002/1097‑0045(20001001)45:2<158::AID‑PROS10>3.0.CO;2‑K 11027415
     [Google Scholar]
  6. SchallyA.V. Comaru-SchallyA.M. NagyA. Hypothalamic hormones and cancer.Front. Neuroendocrinol.200122424829110.1006/frne.2001.0217 11587553
     [Google Scholar]
  7. FrohmanL.A. KinemanR.D. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis.Trends Endocrinol. Metab.200213729930310.1016/S1043‑2760(02)00613‑6 12163232
     [Google Scholar]
  8. SchallyA.V. SzepeshaziK. NagyA. Comaru-SchallyA.M. HalmosG. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.Cell. Mol. Life Sci.20046191042106810.1007/s00018‑004‑3434‑3 15112052
     [Google Scholar]
  9. SchallyA.V. PerezR. BlockN.L. RickF.G. Potentiating effects of GHRH analogs on the response to chemotherapy.Cell Cycle201514569970410.1080/15384101.2015.1010893 25648497
     [Google Scholar]
  10. SchallyA.V. VargaJ.L. EngelJ.B. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.Nat. Clin. Pract. Endocrinol. Metab.200841334310.1038/ncpendmet0677 18084344
     [Google Scholar]
  11. SchallyA.V. VargaJ.L. Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents.Trends Endocrinol. Metab.1999101038339110.1016/S1043‑2760(99)00209‑X 10542394
     [Google Scholar]
  12. BarabutisN. SchallyA.V. Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology.Cell Cycle20109204110411610.4161/cc.9.20.13787 20962577
     [Google Scholar]
  13. TheophanousE. PetrakiC. ScorilasA. The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.Mol. Med.2009157-824224710.2119/molmed.2008.00132 19593408
     [Google Scholar]
  14. BustoR. SchallyA.V. VargaJ.L. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.Proc. Natl. Acad. Sci. USA20029918118661187110.1073/pnas.182433099 12186980
     [Google Scholar]
  15. RickF.G. BuchholzS. SchallyA.V. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.Cell Cycle201211132518252510.4161/cc.20900 22751419
     [Google Scholar]
  16. HohlaF. BuchholzS. SchallyA.V. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.Cell Cycle20098193149315610.4161/cc.8.19.9698 19755849
     [Google Scholar]
  17. RickF.G. SeitzS. SchallyA.V. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.Cell Cycle201211224203421010.4161/cc.22498 23095641
     [Google Scholar]
  18. HohlaF. ModerA. MayrhauserU. Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon.Int. J. Oncol.200833113714310.3892/ijo.33.1.137 18575759
     [Google Scholar]
  19. LeoneS. ChiavaroliA. RecinellaL. Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis.Pharmacol. Res.202015210461410.1016/j.phrs.2019.104614 31874252
     [Google Scholar]
  20. BustinS.A. JenkinsP.J. The growth hormone-insulin-like growth factor-I axis and colorectal cancer.Trends Mol. Med.200171044745410.1016/s1471‑4914(01)02104‑9 11597519
     [Google Scholar]
  21. SamaniA.A. YakarS. LeRoithD. BrodtP. The role of the IGF system in cancer growth and metastasis: overview and recent insights.Endocr. Rev.2007281204710.1210/er.2006‑0001 16931767
     [Google Scholar]
  22. AllenN.E. RoddamA.W. AllenD.S. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk.Br. J. Cancer20059271283128710.1038/sj.bjc.6602471 15756268
     [Google Scholar]
  23. StattinP. BylundA. RinaldiS. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.J. Natl. Cancer Inst.200092231910191710.1093/jnci/92.23.1910 11106682
     [Google Scholar]
  24. Probst-HenschN.M. YuanJ-M. StanczykF.Z. GaoY-T. RossR.K. YuM.C. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai.Br. J. Cancer200185111695169910.1054/bjoc.2001.2172 11742490
     [Google Scholar]
  25. PalmqvistR. HallmansG. RinaldiS. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.Gut200250564264610.1136/gut.50.5.642 11950809
     [Google Scholar]
  26. SimonsC.C.J.M. SchoutenL.J. GodschalkR.W.L. Genetic variants in the insulin-like growth factor pathway and colorectal cancer risk in the Netherlands cohort study.Sci. Rep.20155114126610.1038/srep14126 26381944
     [Google Scholar]
  27. KőváriB. VranicS. MarchioC. SapinoA. CserniG. The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation—further evidence of the presence of a GHRH pathway in these tumors.Hum. Pathol.20176416417010.1016/j.humpath.2017.03.026 28438614
     [Google Scholar]
  28. GanJ. KeX. JiangJ. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1–STAT3/NF-κB signaling.Proc. Natl. Acad. Sci. USA201611351147451475010.1073/pnas.1618582114 27930339
     [Google Scholar]
  29. ChatzistamouI. SchallyA.V. KiarisH. Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers.Eur. J. Endocrinol.2004151339139610.1530/eje.0.1510391 15362970
     [Google Scholar]
  30. ChatzistamouI. VolakakiA.A. SchallyA.V. KiarisH. KittasC. Expression of growth hormone–releasing hormone receptor splice variant 1 in primary human melanomas.Regul. Pept.20081471-3333610.1016/j.regpep.2007.12.008 18255167
     [Google Scholar]
  31. VargaJ.L. SchallyA.V. HorvathJ.E. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.Proc. Natl. Acad. Sci. USA200410161708171310.1073/pnas.0307288101 14755056
     [Google Scholar]
  32. PerezR. SchallyA.V. VidaurreI. RinconR. BlockN.L. RickF.G. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.Oncotarget20123998899710.18632/oncotarget.634 22941871
     [Google Scholar]
  33. CuiT. SchallyA.V. Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1.Oncotarget2018947287452875610.18632/oncotarget.25676 29983893
     [Google Scholar]
  34. BarabutisN. SchallyA.V. SiejkaA. P53, GHRH, inflammation and cancer.EBioMedicine20183755756210.1016/j.ebiom.2018.10.034 30344124
     [Google Scholar]
  35. KiarisH. SchallyA.V. VargaJ.L. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice.Neoplasia20002324225010.1038/sj.neo.7900074 10935510
     [Google Scholar]
  36. HosseiniM. ParvizM. ShabanzadehA.P. The inhibiting role of periaqueductal gray metabotropic glutamate receptor subtype 8 in a rat model of central neuropathic pain.Neurol. Res.202042651552110.1080/01616412.2020.1747730 32245335
     [Google Scholar]
  37. KahánZ. KahánZ. VargaJ.L. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.Breast Cancer Res. Treat.2000601717910.1023/A:1006363230990 10845811
     [Google Scholar]
  38. EngelJ.B. KellerG. SchallyA.V. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.J. Clin. Endocrinol. Metab.20059063614362110.1210/jc.2004‑2179 15784701
     [Google Scholar]
  39. ChatzistamouI. SchallyA.V. VargaJ.L. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone.Anticancer Drugs200112976176810.1097/00001813‑200110000‑00008 11593058
     [Google Scholar]
  40. StangelbergerA. SchallyA.V. VargaJ.L. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.Clin. Cancer Res.2005111495710.1158/1078‑0432.49.11.1 15671527
     [Google Scholar]
  41. HalmosG. SchallyA.V. VargaJ.L. PlonowskiA. RekasiZ. CzompolyT. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.Proc. Natl. Acad. Sci. USA20009719105551056010.1073/pnas.180313097 10962030
     [Google Scholar]
  42. AvanA. MehrabadiS. VelayatiM. Growth-hormone-releasing hormone as a prognostic biomarker and therapeutic target in gastrointestinal cancer.Curr. Cancer Drug Targets202323534635310.2174/1568009623666221228094557 36582060
     [Google Scholar]
  43. HohlaF. SchallyA.V. SzepeshaziK. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.Proc. Natl. Acad. Sci. USA200610339145131451810.1073/pnas.0605309103 16983095
     [Google Scholar]
  44. BuchholzS. SchallyA.V. EngelJ.B. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.Proc. Natl. Acad. Sci. USA200710461943194610.1073/pnas.0610860104 17261802
     [Google Scholar]
  45. SeitzS. RickF.G. SchallyA.V. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.Oncol. Rep.201330141341810.3892/or.2013.2435 23624870
     [Google Scholar]
  46. PerezR. SchallyA.V. PopovicsP. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study.Oncoscience201411066567310.18632/oncoscience.92 25593995
     [Google Scholar]
  47. HavtA. SchallyA.V. HalmosG. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.Proc. Natl. Acad. Sci. USA200510248174241742910.1073/pnas.0506844102 16299104
     [Google Scholar]
  48. SchallyA.V. WangH. HeJ. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.Proc. Natl. Acad. Sci. USA201811547120281203310.1073/pnas.1813375115 30373845
     [Google Scholar]
  49. RecinellaL. ChiavaroliA. VeschiS. Di ValerioV. LattanzioR. OrlandoG. Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice.Biomed. Pharmacother.202214611255410.1016/j.biopha.2021.112554 34923341
     [Google Scholar]
  50. CaiR. ZhangX. WangH. CuiT. HalmosG. ShaW. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.Peptides202215017071610.1016/j.peptides.2021.170716 34952135
     [Google Scholar]
  51. LamharziN. SchallyA.V. KoppánM. GrootK. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.Proc. Natl. Acad. Sci. USA199895158864886810.1073/pnas.95.15.8864 9671770
     [Google Scholar]
  52. SzepeshaziK. SchallyA.V. GrootK. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.Br. J. Cancer200082101724173110.1054/bjoc.2000.1223 10817510
     [Google Scholar]
/content/journals/cctr/10.2174/0115733947278625240304050815
Loading
Growth Hormone-Releasing Hormone as Potential Diagnostic and Therapeutic Target in Colorectal Cancer
Curr Cancer Ther Rev 21, 306 (2025); https://doi.org/10.2174/0115733947278625240304050815
/content/journals/cctr/10.2174/0115733947278625240304050815
/content/journals/cctr/10.2174/0115733947278625240304050815
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer treatment; CRC; GHRH; Growth Factor I (IGF-I); Growth Hormone (GH); prognostic biomarker

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test